Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
ENZY's Cash to Debt is ranked higher than
98% of the 1430 Companies
in the Global Biotechnology industry.

( Industry Median: 54.60 vs. ENZY: No Debt )
ENZY' s 10-Year Cash to Debt Range
Min: 0.43   Max: No Debt
Current: No Debt

Equity to Asset 0.93
ENZY's Equity to Asset is ranked higher than
95% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ENZY: 0.93 )
ENZY' s 10-Year Equity to Asset Range
Min: 0.6   Max: 0.93
Current: 0.93

0.6
0.93
Interest Coverage No Debt
ENZY's Interest Coverage is ranked higher than
76% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ENZY: No Debt )
ENZY' s 10-Year Interest Coverage Range
Min: 8.09   Max: 9999.99
Current: No Debt

8.09
9999.99
Z-Score: 12.95
WACC vs ROIC
1.95%
10.09%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 15.48
ENZY's Operating margin (%) is ranked higher than
92% of the 1162 Companies
in the Global Biotechnology industry.

( Industry Median: -90.24 vs. ENZY: 15.48 )
ENZY' s 10-Year Operating margin (%) Range
Min: -1.51   Max: 18.1
Current: 15.48

-1.51
18.1
Net-margin (%) 16.64
ENZY's Net-margin (%) is ranked higher than
92% of the 1162 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. ENZY: 16.64 )
ENZY' s 10-Year Net-margin (%) Range
Min: -3.75   Max: 17.54
Current: 16.64

-3.75
17.54
ROE (%) 6.32
ENZY's ROE (%) is ranked higher than
89% of the 1309 Companies
in the Global Biotechnology industry.

( Industry Median: -30.42 vs. ENZY: 6.32 )
ENZY' s 10-Year ROE (%) Range
Min: 6.37   Max: 15.5
Current: 6.32

6.37
15.5
ROA (%) 5.67
ENZY's ROA (%) is ranked higher than
91% of the 1438 Companies
in the Global Biotechnology industry.

( Industry Median: -25.96 vs. ENZY: 5.67 )
ENZY' s 10-Year ROA (%) Range
Min: 5.71   Max: 12.16
Current: 5.67

5.71
12.16
ROC (Joel Greenblatt) (%) 13.85
ENZY's ROC (Joel Greenblatt) (%) is ranked higher than
90% of the 1397 Companies
in the Global Biotechnology industry.

( Industry Median: -335.68 vs. ENZY: 13.85 )
ENZY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 13.81   Max: 28.7
Current: 13.85

13.81
28.7
» ENZY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ENZY Guru Trades in Q1 2014

John Paulson 4,271,230 sh (New)
John Paulson 4,177,830 sh (+141.07%)
John Paulson Sold Out
» More
Q2 2014

ENZY Guru Trades in Q2 2014

John Paulson 4,271,230 sh (unchged)
» More
Q3 2014

ENZY Guru Trades in Q3 2014

John Paulson 4,271,230 sh (unchged)
» More
Q4 2014

ENZY Guru Trades in Q4 2014

John Paulson 4,238,275 sh (-0.77%)
» More
» Details

Insider Trades

Latest Guru Trades with ENZY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 26.30
ENZY's P/E(ttm) is ranked higher than
95% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ENZY: 26.30 )
ENZY' s 10-Year P/E(ttm) Range
Min: 16.71   Max: 146.67
Current: 26.3

16.71
146.67
Forward P/E 20.41
ENZY's Forward P/E is ranked higher than
93% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ENZY: 20.41 )
N/A
PE(NRI) 25.30
ENZY's PE(NRI) is ranked higher than
96% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ENZY: 25.30 )
ENZY' s 10-Year PE(NRI) Range
Min: 6.74   Max: 55.87
Current: 25.3

6.74
55.87
P/B 1.50
ENZY's P/B is ranked higher than
95% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 6.80 vs. ENZY: 1.50 )
ENZY' s 10-Year P/B Range
Min: 0.98   Max: 11
Current: 1.5

0.98
11
P/S 4.52
ENZY's P/S is ranked higher than
88% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 37.92 vs. ENZY: 4.52 )
ENZY' s 10-Year P/S Range
Min: 1.17   Max: 4.6
Current: 4.52

1.17
4.6
POCF 107.50
ENZY's POCF is ranked higher than
90% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ENZY: 107.50 )
ENZY' s 10-Year POCF Range
Min: 9.93   Max: 109.38
Current: 107.5

9.93
109.38
EV-to-EBIT 17.63
ENZY's EV-to-EBIT is ranked higher than
97% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ENZY: 17.63 )
ENZY' s 10-Year EV-to-EBIT Range
Min: 7.2   Max: 61.8
Current: 17.63

7.2
61.8
Current Ratio 7.97
ENZY's Current Ratio is ranked higher than
84% of the 1394 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. ENZY: 7.97 )
ENZY' s 10-Year Current Ratio Range
Min: 1.78   Max: 7.97
Current: 7.97

1.78
7.97
Quick Ratio 5.52
ENZY's Quick Ratio is ranked higher than
77% of the 1394 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. ENZY: 5.52 )
ENZY' s 10-Year Quick Ratio Range
Min: 1.27   Max: 5.65
Current: 5.52

1.27
5.65
Days Inventory 340.39
ENZY's Days Inventory is ranked higher than
78% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ENZY: 340.39 )
ENZY' s 10-Year Days Inventory Range
Min: 121.07   Max: 333.94
Current: 340.39

121.07
333.94
Days Sales Outstanding 128.19
ENZY's Days Sales Outstanding is ranked higher than
73% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 128.03 vs. ENZY: 128.19 )
ENZY' s 10-Year Days Sales Outstanding Range
Min: 108   Max: 128.19
Current: 128.19

108
128.19

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.30
ENZY's Price/Net Cash is ranked higher than
79% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 105.00 vs. ENZY: 9.30 )
ENZY' s 10-Year Price/Net Cash Range
Min: 7.72   Max: 10.39
Current: 9.3

7.72
10.39
Price/Net Current Asset Value 4.50
ENZY's Price/Net Current Asset Value is ranked higher than
90% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 41.60 vs. ENZY: 4.50 )
ENZY' s 10-Year Price/Net Current Asset Value Range
Min: 2.84   Max: 6.51
Current: 4.5

2.84
6.51
Price/Tangible Book 1.60
ENZY's Price/Tangible Book is ranked higher than
96% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 9.90 vs. ENZY: 1.60 )
ENZY' s 10-Year Price/Tangible Book Range
Min: 1.18   Max: 6.81
Current: 1.6

1.18
6.81
Price/Median PS Value 1.70
ENZY's Price/Median PS Value is ranked higher than
76% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 3.04 vs. ENZY: 1.70 )
ENZY' s 10-Year Price/Median PS Value Range
Min: 0.88   Max: 1.45
Current: 1.7

0.88
1.45
Price/Graham Number 1.40
ENZY's Price/Graham Number is ranked higher than
98% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ENZY: 1.40 )
ENZY' s 10-Year Price/Graham Number Range
Min: 1.15   Max: 3.35
Current: 1.4

1.15
3.35
Earnings Yield (Greenblatt) 5.50
ENZY's Earnings Yield (Greenblatt) is ranked higher than
96% of the 1388 Companies
in the Global Biotechnology industry.

( Industry Median: -5.90 vs. ENZY: 5.50 )
ENZY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.6   Max: 13.9
Current: 5.5

1.6
13.9

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:EZ4.Germany,
» More Articles for ENZY

Headlines

Articles On GuruFocus.com
ENZYMOTEC 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General a Nov 01 2014 
Kessler Topaz Meltzer & Check, LLP Reminds Enzymotec Ltd. (ENZY) Shareholders of Class Action Lawsui Oct 15 2014 
Saxena White P.A. Files Securities Fraud Class Action Against Enzymotec Ltd. Oct 15 2014 
What Drives St. Jude Medical to Be More Diversified? Apr 30 2014 


More From Other Websites
2015-03-26 Launch in Swedish pharmacies of Enzymatica's ColdZyme® OneCold against common colds Mar 26 2015
Enzymotec Ltd. Reports a Decision of the U.S. Patent and Trademark Office Mar 24 2015
Enzymotec Ltd. Reports a Decision of the U.S. Patent and Trademark Office Mar 24 2015
2015-03-23 Notice of 2015 Annual General Meeting in Enzymatica AB Mar 23 2015
Enzymotec Ltd. Granted New Patents in the United States and Australia Relevant to Phospholipid-Based... Mar 13 2015
Enzymotec Ltd. Granted New Patents in the United States and Australia Relevant to Phospholipid-Based... Mar 13 2015
ENZYMOTEC LTD. Financials Mar 12 2015
Enzymotec (ENZY) in Focus: Stock Surges 10.3% - Tale of the Tape Feb 24 2015
Enzymotec posts 4Q profit Feb 18 2015
Enzymotec posts 4Q profit Feb 18 2015
Enzymotec Ltd. Reports Fourth Quarter and Full Year 2014 Unaudited Financial Results Feb 18 2015
Enzymotec Ltd. Reports Fourth Quarter and Full Year 2014 Unaudited Financial Results Feb 18 2015
Enzymotec Ltd. Announces the Appointment of Holger Liepmann to Its Board of Directors Feb 13 2015
Enzymotec Ltd. Announces the Appointment of Holger Liepmann to Its Board of Directors Feb 13 2015
2015-02-10 Enzymatica's new CEO Fredrik Lindberg takes office Feb 10 2015
Enzymotec to Report Fourth Quarter and Full Year 2014 Financial Results Feb 04 2015
Enzymotec Ltd. Announces Favorable Response From the Australian Patent Office Feb 03 2015
Enzymotec Ltd. Initiates Clinical Study of Vayacog in Mild Cognitive Impairment Jan 20 2015
Enzymotec Ltd. Announces an Extraordinary General Meeting of Shareholders Jan 02 2015
2014-12-17 Extraordinary General Meeting of Enzymatica AB cancelled Dec 17 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK